ChinaBio Today -- Despite the continuing economic crisis, investment in China biopharma continued apace last week. There weren’t any spectacularly huge deals, only the normal-sized deals on which biopharmas depend to steadily build their businesses.
ChinaBio Today -- Despite the continuing economic crisis, investment in China biopharma continued apace last week. There weren’t any spectacularly huge deals, only the normal-sized deals on which biopharmas depend to steadily build their businesses.
